This is a narrative, non-systematic review of preclinical and human data on GLP-1 receptor agonist exposure from before conception through pregnancy. It covers congenital anomalies, hypertensive disorders, gestational diabetes, preterm birth, fetal growth and stillbirth, plus drug washout.
The authors found that human observational data have not shown a clear rise in adverse pregnancy outcomes after periconception exposure. They also state that the evidence is limited by small numbers, observational designs, confounding and incomplete recording of exposure, and that it cannot exclude clinically important risks. These drugs may also improve fertility in some women with obesity and polycystic ovary syndrome, which is why unplanned conceptions are becoming more common.
In clinic, the useful step is to ask. Exposure is probably under-recorded because routine enquiry is not universal. The review advises individualised counselling rather than treating exposure as either proven harmful or proven safe. Product labels advise contraception during treatment, and that advice stands.
- Ask every woman of reproductive age with obesity, diabetes or PCOS about current or recent GLP-1 receptor agonist use, and record it.
- Counsel women on treatment about effective contraception, and about planning a switch or stop before trying to conceive.
- For inadvertent exposure, avoid both false reassurance and alarm; explain that data so far show no clear signal but are limited.
- Review the drug's half-life and washout when advising on timing, and involve the prescriber.
- Consider early dating and a detailed anomaly scan after exposure, and report the exposure where a registry exists.
Why it matters
Services are meeting exposed pregnancies without guidance, and the honest answer is uncertainty rather than reassurance.
Don't overread it
A non-systematic review of observational data cannot show that exposure is safe.
The statistics, in plain English
This review reports no pooled effect sizes, so there is no confidence interval to read. 'No clear signal' in small observational studies is not the same as 'no risk': studies with few exposed pregnancies can miss uncommon harms, and women who take these drugs differ from those who do not in ways that affect outcomes.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for obstetrics & gynaecology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free